Fast Five Quiz: Are You Prepared to Confront Metastatic Breast Cancer?

Winston W. Tan, MD; Stefania Morganti, MD


December 15, 2022

Endocrine therapy in combination with CDK4/6 inhibitors is the recommended first-line treatment for patients with hormone receptor (ER- and/or PR)–positive/HER2-negative metastatic breast disease without life-threatening disease. Chemotherapy is generally considered in further lines, when tumors develop endocrine resistance, or for patients with visceral crisis for whom a rapid response and tumor shrinkage are needed. Many endocrine agents are available (eg, fulvestrant, aromatase inhibitors, oral SERDs, etc.) that are usually administered in combination with targeted agents (CDK 4/6 inhibitors, PIK3CA inhibitors, mTOR inhibitors).

Learn more about the management of metastatic breast cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.